185 related articles for article (PubMed ID: 19211505)
21. Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma.
Ge K; DuHadaway J; Du W; Herlyn M; Rodeck U; Prendergast GC
Proc Natl Acad Sci U S A; 1999 Aug; 96(17):9689-94. PubMed ID: 10449755
[TBL] [Abstract][Full Text] [Related]
22. STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma.
Brender C; Nielsen M; Kaltoft K; Mikkelsen G; Zhang Q; Wasik M; Billestrup N; Odum N
Blood; 2001 Feb; 97(4):1056-62. PubMed ID: 11159537
[TBL] [Abstract][Full Text] [Related]
23. CD164 identifies CD4
Benoit BM; Jariwala N; O'Connor G; Oetjen LK; Whelan TM; Werth A; Troxel AB; Sicard H; Zhu L; Miller C; Takeshita J; McVicar DW; Kim BS; Rook AH; Wysocka M
Arch Dermatol Res; 2017 Jan; 309(1):11-19. PubMed ID: 27766406
[TBL] [Abstract][Full Text] [Related]
24. Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma.
Kamijo H; Miyagaki T; Shishido-Takahashi N; Nakajima R; Oka T; Suga H; Sugaya M; Sato S
Blood; 2018 Nov; 132(18):1922-1935. PubMed ID: 30194255
[TBL] [Abstract][Full Text] [Related]
25. The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome.
da Silva Almeida AC; Abate F; Khiabanian H; Martinez-Escala E; Guitart J; Tensen CP; Vermeer MH; Rabadan R; Ferrando A; Palomero T
Nat Genet; 2015 Dec; 47(12):1465-70. PubMed ID: 26551667
[TBL] [Abstract][Full Text] [Related]
26. Characterization of bridging integrator 1 (BIN1) as a potential tumor suppressor and prognostic marker in hepatocellular carcinoma.
Pan K; Liang XT; Zhang HK; Zhao JJ; Wang DD; Li JJ; Lian Q; Chang AE; Li Q; Xia JC
Mol Med; 2012 May; 18(1):507-18. PubMed ID: 22281836
[TBL] [Abstract][Full Text] [Related]
27. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
[TBL] [Abstract][Full Text] [Related]
28. Th1 response and cytotoxicity genes are down-regulated in cutaneous T-cell lymphoma.
Hahtola S; Tuomela S; Elo L; Häkkinen T; Karenko L; Nedoszytko B; Heikkilä H; Saarialho-Kere U; Roszkiewicz J; Aittokallio T; Lahesmaa R; Ranki A
Clin Cancer Res; 2006 Aug; 12(16):4812-21. PubMed ID: 16914566
[TBL] [Abstract][Full Text] [Related]
29. MYC phosphorylation at novel regulatory regions suppresses transforming activity.
Wasylishen AR; Chan-Seng-Yue M; Bros C; Dingar D; Tu WB; Kalkat M; Chan PK; Mullen PJ; Huang L; Meyer N; Raught B; Boutros PC; Penn LZ
Cancer Res; 2013 Nov; 73(21):6504-15. PubMed ID: 24030976
[TBL] [Abstract][Full Text] [Related]
30. The c-MYC-interacting proapoptotic tumor suppressor BIN1 is a transcriptional target for E2F1 in response to DNA damage.
Cassimere EK; Pyndiah S; Sakamuro D
Cell Death Differ; 2009 Dec; 16(12):1641-53. PubMed ID: 19629135
[TBL] [Abstract][Full Text] [Related]
31. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
Wang Y; Gu X; Li W; Zhang Q; Zhang C
J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
[TBL] [Abstract][Full Text] [Related]
32. Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma.
Ge K; Minhas F; Duhadaway J; Mao NC; Wilson D; Buccafusca R; Sakamuro D; Nelson P; Malkowicz SB; Tomaszewski J; Prendergast GC
Int J Cancer; 2000 Apr; 86(2):155-61. PubMed ID: 10738240
[TBL] [Abstract][Full Text] [Related]
33. Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.
Xu J; Huang H; Wang S; Chen Y; Yin X; Zhang X; Zhang Y
Arch Dermatol Res; 2020 Sep; 312(7):513-525. PubMed ID: 31676945
[TBL] [Abstract][Full Text] [Related]
34. The role of AHI1 and CDKN1C in cutaneous T-cell lymphoma progression.
Litvinov IV; Kupper TS; Sasseville D
Exp Dermatol; 2012 Dec; 21(12):964-6. PubMed ID: 23171462
[TBL] [Abstract][Full Text] [Related]
35. Bin1 functionally interacts with Myc and inhibits cell proliferation via multiple mechanisms.
Elliott K; Sakamuro D; Basu A; Du W; Wunner W; Staller P; Gaubatz S; Zhang H; Prochownik E; Eilers M; Prendergast GC
Oncogene; 1999 Jun; 18(24):3564-73. PubMed ID: 10380878
[TBL] [Abstract][Full Text] [Related]
36. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
Nihal M; Stutz N; Schmit T; Ahmad N; Wood GS
Cell Cycle; 2011 Apr; 10(8):1303-11. PubMed ID: 21436619
[TBL] [Abstract][Full Text] [Related]
37. Bin1 mediates apoptosis by c-Myc in transformed primary cells.
DuHadaway JB; Sakamuro D; Ewert DL; Prendergast GC
Cancer Res; 2001 Apr; 61(7):3151-6. PubMed ID: 11306501
[TBL] [Abstract][Full Text] [Related]
38. Cutaneous T cell lymphoma expresses immunosuppressive CD80 (B7-1) cell surface protein in a STAT5-dependent manner.
Zhang Q; Wang HY; Wei F; Liu X; Paterson JC; Roy D; Mihova D; Woetmann A; Ptasznik A; Odum N; Schuster SJ; Marafioti T; Riley JL; Wasik MA
J Immunol; 2014 Mar; 192(6):2913-9. PubMed ID: 24523507
[TBL] [Abstract][Full Text] [Related]
39. Notch1 as a potential therapeutic target in cutaneous T-cell lymphoma.
Kamstrup MR; Gjerdrum LM; Biskup E; Lauenborg BT; Ralfkiaer E; Woetmann A; Ødum N; Gniadecki R
Blood; 2010 Oct; 116(14):2504-12. PubMed ID: 20538790
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas.
Kitadate A; Ikeda S; Teshima K; Ito M; Toyota I; Hasunuma N; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
Oncogene; 2016 Jul; 35(28):3692-704. PubMed ID: 26640145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
